Navigation Links
Menon Biosensors Demonstrates Industry Leading Sensitivity Levels for Detection of Tuberculosis and Clostridium difficile
Date:1/9/2014

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Menon Biosensors, Inc. a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens, announced today that its M2 (Molecular Mirroring) nuclear magnetic resonance (NMR) technology successfully detected Mycobacterium tuberculosis (TB) and Clostridium difficile (C. difficile) in studies with more than 500 samples, in concentrations as low as 1 colony-forming unit (CFU) per sample, without any false positives or negatives. The company will present the results of its studies at the Biotech Showcase 2014 in San Francisco on Tuesday, January 14, 2014, at 4:15 p.m. PST.

"With our unique platform detection technology, our scientists were able to develop and optimize our assays for these serious worldwide diseases in just 60 to 90 days, while still delivering unmatched sensitivity," stated Suresh Menon, Ph.D., President of Menon Biosensors. "In these studies the time from sample to result continues to be less than one hour. We plan to continue to demonstrate the speed and sensitivity of our technology in detecting additional pathogens for individual and public health, including food safety and livestock applications, where timely detection and intervention are very important." 

The studies were conducted at Scripps Memorial Hospital laboratories, where Menon employees worked under the supervision of John Spinosa, M.D., Ph.D., pathologist at Scripps La Jolla. The M2 technology detected the presence of TB and C. difficile in concentrations as low as 1 CFU/sample in water and 5 CFU/sample (50-100 CFU/mL) in sputum and stool.  Time from sample-to-result was less than one hour, including sample preparation time that ranged from 5 to 15 minutes depending on the specimen type. Menon Biosensors expects to further optimize these assays for detection of pathogens in sputum and stool to measure even lower concentrations and to publish additional clinical validation data in 2014.

About Menon Biosensors' Platform Technology

Menon Biosensors' M2 technology has been validated through multiple studies with the U.S. government's Biodefense Program. In these studies, conducted in more than 3,000 samples over a six-year period, the technology demonstrated greater than 99 percent accuracy. The tests were conducted in the presence of interferants and near neighbors of the pathogens to be detected. 

Providing accurate results in less than one hour from the time a sample is collected, Menon Biosensors' M2 technology allows medical professionals to quickly treat a pathogen with the appropriate therapeutic. Current diagnosis techniques for many pathogens may require several hours to multiple days for accurate detection, which limits treatment options early in the patient's care. The M2 technology also serves the need for diagnosis in food safety/livestock applications.

Menon Biosensor' platform technology is portable and offers random access testing with no cold chain requirements for the assays. 

About Menon Biosensors, Inc.

Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors' microfluidics and M2 NMR platform technology (classified by the U.S. Government until 2012) provides superior sensitivity and specificity and minimizes sample preparation, providing best in class sample-to-answer pathogen detection. The technology has been validated by respected third parties in more than 3,000 samples over six years.

 


'/>"/>
SOURCE Menon Biosensors
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New phenomenon in nanodisk magnetic vortices
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
4. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
5. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
6. Entinostat Demonstrates Activity in Hodgkins Lymphoma
7. OrbusNeichs Combo Dual Therapy Stentâ„¢ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
8. Nitor Group Demonstrates Direct Product Suite at Direct Implementation and Adoption Summit May 31-June 1
9. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
10. Hark! Group demonstrates first heralded single photon source made from silicon
11. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Chip (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip ... user (Academics Institutes, Diagnostics Centers), Fabrication Technology ... by MarketsandMarkets, the market is expected to ... USD 7.63 Billion in 2015, growing at ...
(Date:5/3/2016)... Boston, Massachusetts (PRWEB) , ... May 03, 2016 ... ... communities will gather at Boston CEO 2016 on May 31st and June 1st ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech + ... conferences, will take place on June 7-8, 2016, at the New York Academy of ... incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout a ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 , ... ... Hill Hospital , for definitive prostate cancer treatment, patients traditionally had two main treatment ... appropriate treatment plan would be made. , New technology has enabled doctors to ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):